NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection

被引：6

作者：

Debes, Jose D. ^{[1
]}

Smith, Coleman I. ^{[1
]}

机构：

[1] Univ Minnesota, Plymouth, MN USA

来源：

HEPATOLOGY | 2012年 / 56卷 / 03期

关键词：

GENOTYPE; 1; PROTEIN; REPLICATION; INHIBITOR; BMS-790052;

D O I：

10.1002/hep.25696

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：797 / 799

页数：3

共 50 条

[31] Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents [J].

McPhee, Fiona ;

Ueland, Joseph ;

Vellucci, Vincent ;

Bowden, Scott ;

Sievert, William ;

Zhou, Nannan .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (04)

[32] Antiviral effect of saikosaponin B2 in combination with daclatasvir on NS5A resistance-associated substitutions of hepatitis C virus [J].

Lee, Wei-Ping ;

Lan, Keng-Li ;

Liao, Shi-Xian ;

Huang, Yi-Hsiang ;

Hou, Ming-Chih ;

Lan, Keng-Hsin .

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (05) :368-374

[33] Fluorescence Resonance Energy Transfer-Based Intracellular Assay for the Conformation of Hepatitis C Virus Drug Target NS5A [J].

Bhattacharya, Dipankar ;

Ansari, Israrul H. ;

Mehle, Andrew ;

Striker, Rob .

JOURNAL OF VIROLOGY, 2012, 86 (15) :8277-8286

[34] Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection [J].

Spengler, Ulrich .

PHARMACOLOGY & THERAPEUTICS, 2018, 183 :118-126

[35] Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy [J].

Itakura, Jun ;

Kurosaki, Masayuki ;

Higuchi, Mayu ;

Takada, Hitomi ;

Nakakuki, Natsuko ;

Itakura, Yoshie ;

Tamaki, Nobuharu ;

Yasui, Yutaka ;

Suzuki, Shoko ;

Tsuchiya, Kaoru ;

Nakanishi, Hiroyuki ;

Takahashi, Yuka ;

Maekawa, Shinya ;

Enomoto, Nobuyuki ;

Izumi, Namiki .

PLOS ONE, 2015, 10 (09)

[36] Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China [J].

Lu, Jie ;

Feng, Yupeng ;

Chen, Lichang ;

Zeng, Zhengyu ;

Liu, Xianliang ;

Cai, Wei ;

Wang, Hui ;

Guo, Xiaolei ;

Zhou, Huijuan ;

Tao, Wanyin ;

Xie, Qing .

FRONTIERS IN MICROBIOLOGY, 2019, 10

[37] Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis [J].

de Torres Santos, Ana Paula ;

Martins Silva, Vanessa Cristina ;

Mendes-Correa, Maria Cassia ;

Lemos, Marcilio Figueiredo ;

Malta, Fernanda de Mello ;

Ferraz Santana, Rubia Anita ;

Fernando Dastoli, Gregorio Tadeu ;

Duarte de Castro, Vanessa Fusco ;

Rebello Pinho, Joao Renato ;

Moreira, Regina Celia .

REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2022, 64

[38] Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C [J].

Stirnimann, Guido .

EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (17) :2609-2622

[39] Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A [J].

Fernandes, Fiona ;

Ansari, Israr-ul H. ;

Striker, Rob .

PLOS ONE, 2010, 5 (03)

[40] Self-association and conformational variation of NS5A domain 1 of hepatitis C virus [J].

Beldar, Serap ;

Manimekalai, Malathy Sony Subramanian ;

Cho, Nam-Joon ;

Baek, Kwanghee ;

Gruber, Gerhard ;

Yoon, Ho Sup .

JOURNAL OF GENERAL VIROLOGY, 2018, 99 (02) :194-208

← 1 2 3 4 5 →